To verify the capacity of CASZ1 to inhibit HCC progression in vivo, we established subcutaneous xenograft tumor models and orthotopic xenograft tumor models using luciferase-labelled HCCLM3CASZ1, PLC/PRF/5shCASZ1 and their control cells. Here, CASZ1 is linked to neoplasm.